Subject(s)
Osteoarthropathy, Primary Hypertrophic/diagnosis , Osteoarthropathy, Primary Hypertrophic/urine , Prostaglandins E/urine , Prostanoic Acids/urine , Adolescent , Adult , Alleles , Biomarkers/urine , Case-Control Studies , Hand , Humans , Hydroxyprostaglandin Dehydrogenases/genetics , Male , Middle Aged , Mutation , Organic Anion Transporters/genetics , Phenotype , Young AdultABSTRACT
Dysfunction of perivascular adipose tissue of mesenteric bed participates in the pathophysiology of high blood pressure linked to metabolic syndrome. Thus, it might consider a new therapeutic objective to take account in cardiovascular and metabolic diseases. Besides its antihypertensive effect, there is a growing interest on the pleiotropic actions of losartan, an angiotensin II type 1 (AT1) receptor antagonist. The aim of the study was to analyze the actions of losartan treatment on adiposity index and prostanoids release from mesenteric vascular bed and its relationship with blood pressure as well as homeostasis model of assessment of insulin resistance (HOMA-IR) in Sprague-Dawley rats under a high-fat (HF) diet for 8 weeks. Four groups were used: control (C), HF diet (HF, 50%, w/w bovine fat), losartan-treated (CL8, 30mg/kg/body weight/day in the drinking water) and losartan-treated HF diet (HFL, both treatments). A high-fat diet incremented systolic blood pressure, HOMA-IR, adiposity of mesenteric vascular bed and the release of vasoconstrictor prostanoids such as thromboxane (TX) B2 and prostaglandin (PG) F2α as well as PGE2, an inflammatory prostanoid in a context of insulin resistance and hypertension. We found a positive correlation between adiposity index and systolic blood pressure. Also, both parameters are positive correlated with the HOMA IR index. Moreover, we also found that these prostanoids release correlate with systolic blood pressure as well as with mesenteric vascular bed adiposity index. Losartan treatment prevented all these alterations and normalized the PGI2/TXA2 ratio in high-fat fed rats. We conclude that losartan may play beneficial actions on perivascular adipose tissue alterations and endothelial dysfunction through restoration of normal balance of vasoactive substances in this model
La disfunción del tejido adiposo perivascular del lecho mesentérico posee una participación en la fisiopatología de la hipertensión arterial relacionada con el síndrome metabólico. Por lo tanto, podría considerarse como un nuevo blanco terapéutico en las enfermedades cardiovasculares y metabólicas. Además de su efecto antihipertensivo, existe un interés creciente en las acciones pleiotrópicas de losartán, antagonista del receptor de angiotensina II. El objetivo del estudio fue analizar las acciones de losartán sobre el índice de adiposidad y la liberación de prostanoides del lecho vascular mesentérico y su relación con la presión arterial, así como en el índice HOMA-IR (modelo de evaluación homeostático de la resistencia a la insulina) en ratas con dieta alta en grasas. Observamos que la dieta alta en grasas incrementó la adiposidad del lecho vascular mesentérico y la liberación de prostanoides vasoconstrictores como tromboxano (TX) B2 y prostaglandina (PG) F2α, así como la PGE2, un prostanoide inflamatorio en el contexto de resistencia a la insulina e hipertensión. También encontramos una correlación positiva entre el índice de adiposidad y la presión arterial sistólica y ambos parámetros se correlacionan positivamente con el índice HOMA IR. Adicionalmente observamos que la liberación de estos prostanoides se correlaciona con la presión arterial sistólica, así como con el índice de adiposidad del lecho vascular mesentérico. El tratamiento con losartán previno todas estas alteraciones y normalizó la relación PGI2/TXA2 en ratas alimentadas con una dieta alta en grasa. Concluimos entonces que losartán puede ejercer acciones beneficiosas sobre las alteraciones del tejido adiposo perivascular y la disfunción endotelial a través de la restauración del equilibrio normal de sustancias vasoactivas en este modelo experimental
Subject(s)
Animals , Rats , Hypertension/drug therapy , Losartan/pharmacokinetics , Mesenteric Vascular Occlusion/prevention & control , Obesity/physiopathology , Metabolic Syndrome/physiopathology , Diet, High-Fat/adverse effects , Disease Models, Animal , Antihypertensive Agents/pharmacokinetics , Vascular Resistance/drug effects , Hypertension/physiopathology , Prostanoic AcidsABSTRACT
INTRODUCTION: Prostaglandin E-major urinary metabolite (PGE-MUM) is a novel biomarker reflecting endoscopic activity in ulcerative colitis (UC). However, there are no studies investigating the efficacy of PGE-MUM as a biomarker for predicting relapse. We investigated whether PGE-MUM can predict clinical relapse of UC. METHODS: The measurement of PGE-MUM and endoscopic evaluation were performed in 70 patients with UC in clinical remission. The optimal cutoff values predicting relapse and relapse-free rate were analyzed. RESULTS: Sixteen patients (22.9%) relapsed during the 12-month follow-up. The median PGE-MUM value of relapsed patients at entry was significantly higher than that of patients in clinical remission (P = 0.008). The cutoff value of PGE-MUM predicting future relapse was 25.2 µg/g Cr by receiver-operating characteristic (ROC) analysis, and the area under the ROC curve was 0.721 (95% confidence interval: 0.556-0.886). The relapse-free rate of patients with PGE-MUM ≥25.2 µg/g Cr was significantly lower than that in patients with PGE-MUM <25.2 µg/g Cr (log-rank test: P < 0.001). The ROC analysis of UC patients with disease duration more than 1-8 years showed that duration of more than 5 years had the largest area under the ROC curve 0.821 (95% confidence interval: 0.583-1.000) and that the optimal cutoff value was 26.3 µg/g Cr. DISCUSSION: PGE-MUM is a reliable biomarker for predicting future relapse, particularly in UC patients with long-disease duration.
Subject(s)
Colitis, Ulcerative/diagnosis , Prostaglandins/metabolism , Prostanoic Acids/urine , Adolescent , Adult , Aged , Aged, 80 and over , Biomarkers/urine , Colitis, Ulcerative/therapy , Colitis, Ulcerative/urine , Colonoscopy , Feasibility Studies , Female , Follow-Up Studies , Humans , Male , Middle Aged , Predictive Value of Tests , Prognosis , Prostanoic Acids/metabolism , ROC Curve , Recurrence , Reproducibility of Results , Risk Assessment/methods , Severity of Illness Index , Young AdultABSTRACT
Phytoprostanes (PhytoPs) and phytofurans (PhytoFs) are isoprostanoids that result from the peroxidation of α-linolenic acid and are biomarkers of oxidative stress in plants and humans. These compounds exhibit several interesting biological activities (e.g. neuroprotection and anti-inflammatory activities). The aim of this research was to add value to coffee pulp (CP), cocoa husk (CH) and cocoa pod husk (CPH) by identifying and quantifying PhytoPs and PhytoFs by liquid chromatography-tandem mass spectrometry. The contents of PhytoPs and PhytoFs in CP, CH, and CPH were, respectively, 654.6, 474.3 and 179.9, and 543.2, 278.0 and 393.8 ng per g dry weight (dw). The main PhytoP found in CP (171.37 ng per g dw) and CPH (37.12 ng per g dw) was 9-epi-9-F1t-PhytoP, while ent-9-L1t-PhytoP was the most abundant in CH (109.78 ng per g dw). The main PhytoF found in all sources was ent-16(RS)-13-epi-ST-Δ14-9-PhytoF, at 196.56, 126.22, and 207.57 ng per g dw in CP, CH, and CPH, respectively. We provide the first complete profile of PhytoPs and PhytoFs for these agro-residues, which could be used in the functional food industry for enriching food or as nutritional supplements.
Subject(s)
Cacao/chemistry , Coffee/chemistry , Furans/analysis , Furans/isolation & purification , Prostanoic Acids/analysis , Prostanoic Acids/isolation & purification , Biomarkers , Chromatography, High Pressure Liquid , Fatty Acids/isolation & purification , Oxidative Stress , Plant Extracts/chemistry , Tandem Mass SpectrometryABSTRACT
BACKGROUND: We recently reported on a hereditary enteropathy associated with a gene encoding a prostaglandin transporter and referred to as chronic enteropathy associated with SLCO2A1 gene (CEAS). Crohn's disease (CD) is a major differential diagnosis of CEAS, because these diseases share some clinical features. Therefore, there is a need to develop a convenient screening test to distinguish CEAS from CD. AIM: To examine whether prostaglandin E major urinary metabolites (PGE-MUM) can serve as a biomarker to distinguish CEAS from CD. METHODS: This was a transactional study of 20 patients with CEAS and 98 patients with CD. CEAS was diagnosed by the confirmation of homozygous or compound heterozygous mutation of SLCO2A1. We measured the concentration of PGE-MUM in spot urine by radioimmunoassay, and the concentration was compared between the two groups of patients. We also determined the optimal cut-off value of PGE-MUM to distinguish CEAS from CD by receiver operating characteristic (ROC) curve analysis. RESULTS: Twenty Japanese patients with CEAS and 98 patients with CD were enrolled. PGE-MUM concentration in patients with CEAS was significantly higher than that in patients with CD (median 102.7 vs 27.9 µg/g × Cre, P < 0.0001). One log unit increase in PGE-MUM contributed to 7.3 increase in the likelihood for the diagnosis of CEAS [95% confidence interval (CI) 3.2-16.7]. A logistic regression analysis revealed that the association was significant even after adjusting confounding factors (adjusted odds ratio 29.6, 95%CI 4.7-185.7). ROC curve analysis revealed the optimal PGE-MUM cut-off value for the distinction of CEAS from CD to be 48.9 µg/g × Cre with 95.0% sensitivity and 79.6% specificity. CONCLUSION: PGE-MUM measurement is a convenient, non-invasive and useful test for the distinction of CEAS from CD.
Subject(s)
Intestinal Diseases/diagnosis , Organic Anion Transporters/genetics , Prostanoic Acids/urine , Ulcer/diagnosis , Adult , Colon/pathology , Crohn Disease/diagnosis , Crohn Disease/urine , Diagnosis, Differential , Female , Humans , Ileum/pathology , Intestinal Diseases/genetics , Intestinal Diseases/pathology , Intestinal Diseases/urine , Male , Middle Aged , Mutation , Organic Anion Transporters/metabolism , Prostaglandins E/metabolism , Prostanoic Acids/metabolism , Ulcer/genetics , Ulcer/pathology , Ulcer/urineABSTRACT
Despite recent advances in our understanding of the biological processes leading to the development and progression of cancer, there is still a need for new and effective agents to treat this disease. Phytoprostanes (PhytoPs) and phytofurans (PhytoFs) are non-enzymatically oxidized products of α-linolenic acid that are present in seeds and vegetable oils. They have been shown to possess anti-inflammatory and apoptosis-promoting activities in macrophages and leukemia cells, respectively. In this work, seven PhytoPs (PP1-PP7) and one PhytoFs (PF1) were evaluated for their cytotoxic, chemosensitization, and anti-migratory activities using the MCF-7 and MDA-MB-231 breast cancer cell lines. Among the tested compounds, only three PhytoPs had a significant effect on cell viability compared to the control group: Ent-9-L1-PhytoP (PP6) decreased cell viability in both cell lines, while 16-F1t-PhytoP (PP1) and 9-L1-PhytoP (PP5) decreased viability of MCF-7 and MDA-MB-231 cells, respectively. When combined with a sub-cytotoxic dose of doxorubicin, these three PhytoPs displayed significantly enhanced cytotoxic effects on MCF-7 cells while the chemotherapeutic drug alone had no effect. In cellular motility assays, Ent-9-(RS)-12-epi-ST-Δ10-13-PhytoF could significantly inhibit cellular migration of MDA-MB-231 cells. In addition, Ent-9-(RS)-12-epi-ST-Δ10-13-PhytoF also enhanced cellular adhesion of MDA-MB-231 cells.
Subject(s)
Antineoplastic Agents/pharmacology , Breast Neoplasms/drug therapy , Breast Neoplasms/pathology , Cell Movement/drug effects , Furans/pharmacology , Prostanoic Acids/pharmacology , alpha-Linolenic Acid/chemistry , Antineoplastic Agents/chemistry , Cell Line, Tumor , Cell Proliferation/drug effects , Cell Survival/drug effects , Drug Screening Assays, Antitumor , Female , Furans/chemistry , Humans , MCF-7 Cells , Oxidation-Reduction , Prostanoic Acids/chemistryABSTRACT
La pérdida del rol modulador del endotelio podría estar implicada en la patogénesis de las complicaciones vasculares diabéticas. Los compuestos de metales de transición tales como wolframio y vanadio se han propuesto como posibles agentes en el tratamiento de la diabetes al simular los efectos de la insulina. El lecho vascular mesentérico interviene en la resistencia vascular y constituye una fuente de compuestos vasoactivos como los prostanoides. El objetivo de este trabajo fue estudiar los efectos de los tratamientos con tungstato de sodio y sulfato de vanadilo sobre los parámetros metabólicos y la liberación de prostanoides del lecho vascular mesentérico en un modelo experimental de diabetes inducida por estreptozotocina. En ratas diabéticas se observó un aumento significativo de los niveles plasmáticos de glucosa, triglicéridos y colesterol total. Por su parte, se observó una reducción significativa en la liberación de los prostanoides vasodilatadores como la prostaciclina y la prostaglandina E2 y del vasoconstrictor tromboxano A2 por el lecho vascular mesentérico. Tanto el tungstato de sodio como el sulfato de vanadilo normalizaron la glucemia, la trigliceridemia y la colesterolemia en las ratas diabéticas. Por otra parte, solo el tratamiento con tungstato de sodio revirtió la reducción en la liberación de prostanoides vasodilatadores, mejorando en los animales diabéticos la relación prostaciclina/tromboxano, un indicador de disfunción vascular. En conclusión, a diferencia del sulfato de vanadilo, el tungstato de sodio demuestra ser más eficaz para controlar las alteraciones metabólicas y de la producción de prostanoides vasodilatadores observadas en la diabetes experimental inducida por estreptozotocina
The loss of the modulator role of the endothelium could be involved in the pathogenesis of diabetic vascular complications. Transition metal compounds, such as tungsten and vanadium, have been proposed as possible agents in the treatment of diabetes by simulating the effects of insulin. The mesenteric vascular bed intervenes in vascular resistance and is a source of vasoactive compounds, such as prostanoids. The aim of this work was to study the effects of sodium tungstate and vanadyl sulphate treatments on the metabolic parameters and the release of prostanoids of the mesenteric vascular bed in an experimental model of Streptozotocin-induced diabetes. In diabetic rats, a significant increase was observed in plasma levels of glucose, triglycerides and total cholesterol. On the other hand, there was a significant reduction in the release of vasodilator prostanoids, such as prostacyclin and prostaglandin E2 and vasoconstrictor thromboxane A2 through the mesenteric vascular bed. Both sodium tungstate and vanadyl sulphate normalised glycaemia, triglyceridaemia and cholesterolaemia in rats diabetics. On the other hand, only treatment with sodium tungstate reversed the reduction in the release of vasodilator prostanoids, improving in diabetic animals the prostacyclin/thromboxane ratio, an indicator of vascular dysfunction. In conclusion, unlike vanadyl sulphate, sodium tungstate is shown to be more effective in controlling metabolic changes and the production of vasodilator prostanoids observed in experimental diabetes induced by streptozotocin
Subject(s)
Animals , Rats , Tungsten Compounds/pharmacology , Vanadium Compounds/pharmacology , Prostanoic Acids/physiology , Mesenteric Arteries , Mesenteric Arteries/physiology , Diabetes Mellitus, Experimental/physiopathology , RatsABSTRACT
BACKGROUND: Dysregulation of the prostaglandin E2 (PGE2) signaling pathway has been implicated in interstitial pneumonia (IP) pathogenesis. Due to the unstable nature of PGE2, available detection methods may not precisely reflect PGE2 levels. We explored the clinical usefulness of measuring stable prostaglandin E-major urinary metabolite (PGE-MUM) with respect to pathogenesis and extent of chronic fibrosing IP (CFIP), including idiopathic pulmonary fibrosis (IPF), as PGE-MUM is reflective of systemic PGE2 production. METHODS: PGE-MUM was measured by radioimmunoassay in controls (n = 124) and patients with lung diseases (bronchial asthma (BA): n = 78, chronic obstructive pulmonary disease (COPD): n = 33, CFIP: n = 44). Extent of lung fibrosis was assessed by fibrosing score (FS) of computed tomography (CT) (FS1-4). Immunohistochemical evaluation of COX-2 was performed to find PGE2 producing cells in IPF. Human bronchial epithelial cells (HBEC) and lung fibroblasts (LFB) were used in in vitro experiments. RESULTS: Compared to control, PGE-MUM levels were significantly elevated in CFIP. PGE-MUM levels were positively correlated with FS, and inversely correlated with %DLCO in IP (FS 1-3). COX-2 was highly expressed in metaplastic epithelial cells in IPF, but lower expression of EP2 receptor was demonstrated in LFB derived from IPF. TGF-ß induced COX-2 expression in HBEC. CONCLUSIONS: PGE-MUM, elevated in CFIP, is a promising biomarker reflecting disease activity. Metaplastic epithelial cells can be a source of elevated PGE-MUM in IPF.
Subject(s)
Idiopathic Pulmonary Fibrosis/metabolism , Lung Diseases, Interstitial/metabolism , Lung/metabolism , Prostanoic Acids/analysis , Urine/chemistry , Adult , Aged , Aged, 80 and over , Biomarkers/metabolism , Cyclooxygenase 2/metabolism , Epithelial Cells/metabolism , Female , Fibroblasts/metabolism , Humans , Idiopathic Pulmonary Fibrosis/diagnostic imaging , Idiopathic Pulmonary Fibrosis/pathology , Japan/epidemiology , Lung/pathology , Lung Diseases, Interstitial/diagnostic imaging , Lung Diseases, Interstitial/pathology , Male , Middle Aged , Prostaglandins/metabolism , Transforming Growth Factor beta/metabolismABSTRACT
OBJECTIVES: Prostaglandin E-major urinary metabolite (PGE-MUM) is a useful biomarker for adult ulcerative colitis (UC) activity. In the present study, we evaluated whether PGE-MUM can also be a biomarker of pediatric UC activity and compared its efficacy in predicting UC activity with that of C-reactive protein and erythrocyte sedimentation rate. METHODS: Twenty-nine pediatric patients with UC (8-18 years) and 29 healthy age- and sex-matched subjects were enrolled. UC activity was evaluated using the Pediatric Ulcerative Colitis Activity Index, highest Mayo endoscopic scoring (Mayo), and Matts grading (Matts) for histologic scoring, and the sum of Mayo (total of 6 segments) and Matts in all patients with UC. PGE-MUM levels were measured using a radioimmunoassay. RESULTS: PGE-MUM levels were elevated in endoscopically and histologically active UC patients, but not in patients with endoscopic and histologic remission or controls. PGE-MUM levels positively and significantly correlated with UC activity. PGE-MUM levels were positively correlated with Pediatric Ulcerative Colitis Activity Index (râ=â0.594), highest Mayo (râ=â0.462), the sum of Mayo (râ=â0.694), and the sum of Matts (râ=â0.613), but not with highest Matt (râ=â0.352). The sum of Mayo and the sum of Matts, which reflect total colon inflammation, showed highest correlation with PGE-MUM. C-reactive protein levels did not correlate with any UC activity scores. Erythrocyte sedimentation rate exhibited correlation (râ=â0.490) with the sum of Mayo only. CONCLUSIONS: PGE-MUM is a reliable biomarker that reflects both the endoscopic and histologic activity of the entire colon in pediatric UC.
Subject(s)
Colitis, Ulcerative/diagnosis , Prostanoic Acids/urine , Severity of Illness Index , Adolescent , Biomarkers/urine , Case-Control Studies , Child , Child, Preschool , Colitis, Ulcerative/pathology , Colitis, Ulcerative/urine , Colonoscopy , Female , Humans , Infant , Male , Prospective Studies , Regression Analysis , Sensitivity and SpecificityABSTRACT
GC-MS and GC-MS/MS of pentafluorobenzyl (PFB) ester trimethylsilyl (TMS) ether (PFB-TMS) derivatives of hydroxylated long-chain fatty acids including arachidonic acid metabolites, the eicosanoids, in the electron-capture negative-ion chemical ionization (ECNICI) mode are the most sensitive and accurate approaches to quantify carboxyl groups-containing compounds in complex biological fluids such as plasma and urine. Under ECNICI conditions, PFB-TMS derivatives of eicosanoids ionize to form very few ions, with the carboxylates [M-PFB]- being typically the most intense. Less intense ions may be additionally formed by consecutive neutral loss (NL) of trimethylsilanol (TMSOH, 90Da) groups ([M-PFB-(TMSOH)n]-). By using [1,1-18O2]- and [1,ω-18O2]-eicosanoids, we studied ion processes following collisionally activated dissociation (CAD) of the precursor ions [M-PFB]-. We found that CAD resulted in formation of product ions due to NL of a TMS18OH (92Da) group in monocarboxylic and of a PFB18OH (200Da) group in dicarboxylic eicosanoids. TMS18OH NL implies an intra-molecular transfer of the TMS group from hydroxyl groups to their carboxylate anions [M-PFB]-. From a mechanistic point of view, this rearrangement may explain formation of unique product ions in GC-MS/MS of eicosanoids under ECNICI conditions. From the quantitative point of view, quantification by GC-MS/MS of product ions due to [M-PFB-(TMSOH)n]- and [M-PFB-TMS18OH-(TMSOH)n-1]-would reveal incorrect data, if [1,1-18O2]-eicosanoids are used as internal standards and if no correction for the 18O-loss is performed. In 18O-labelled dicarboxylic eicosanoids, such as the major urinary metabolite (MUM) of E prostaglandins, i.e., [1,ω-18O2]-PGE-MUM), no TMS ester/TMS ether rearrangement was observed. Yet, 18O-loss occurred upon CAD of [M-PFB]- due to NL of PFB18OH (200Da). In both cases the extent of 18O-loss needs to be determined and considered for accurate quantification of monocarboxylic acids such as 8-isoprostaglandin F2α (8-iso-PGF2α) and dicarboxylic eicosanoids such as PGE-MUM.
Subject(s)
Eicosanoids/analysis , Fluorobenzenes/chemistry , Gas Chromatography-Mass Spectrometry/methods , Trimethylsilyl Compounds/chemistry , Esters/chemistry , Humans , Oxygen Isotopes/analysis , Oxygen Isotopes/urine , Prostanoic Acids/analysis , Prostanoic Acids/urine , Tandem Mass Spectrometry/methodsABSTRACT
With the development of new therapeutic approaches, the ultimate goal of ulcerative colitis (UC) treatment is not only clinical remission but also mucosal healing. Successful mucosal healing has been associated with a dramatic risk reduction in UC recurrence and colitis-associated cancer development, which are the most critical complications of UC. However, invasive tests such as colonoscopy and biopsy are required to evaluate mucosal healing. Therefore, frequent examinations are unsuitable for UC patients. Mucosal inflammation of the colon and prostaglandin E2 production are assumed to be correlated; therefore, we considered that prostaglandin E-major urinary metabolite (PGE-MUM; 7-hydroxy-5,11-diketotetranor-prosta-1,16-dioic acid) may be a surrogate biomarker of UC activity. In this review, we propose that PGE-MUM levels reflect the colonoscopic and histological appearance of UC, suggesting that it is a more sensitive biomarker than those previously utilized for UC-related mucosal inflammation. According to the 'organ-specific chronic inflammation-carcinoma sequence' theory, by measuring PGE-MUM periodically, it would be possible to control inflammation, with subsequent prevention of UC recurrence and colitis-associated cancer development. The measurement of urine samples for PGE-MUM - a simple, noninvasive method - can reduce the patient burden as well as medical costs, suggesting its potential for application in routine practice.
Subject(s)
Colitis, Ulcerative/urine , Prostanoic Acids/urine , Biomarkers/urine , Biopsy , Carcinogenesis/immunology , Carcinoma/immunology , Colitis, Ulcerative/immunology , Colitis, Ulcerative/pathology , Colonic Neoplasms/immunology , Colonoscopy , Dinoprostone/immunology , Enteritis/immunology , Enteritis/pathology , Humans , Intestinal Mucosa/immunology , Intestinal Mucosa/pathology , Prostanoic Acids/immunologyABSTRACT
Enantiopure stereomers of rosaprostol 1, an antiulcer drug, were synthesized from diastereomeric building blocks (-)-5a and (+)-5b. Conversion of (-)-5a into rosaprostol stereomer (-)-(1S,2R,5R)-1a was accomplished in nine steps in 18% overall yield. In this sequence, fully diastereoselective hydrogeneration of the endocyclic carbon double bond in the cyclopentenone ring was key, generating a new stereogenic center (C-2 in 1a). C-5 epimeric rosaprostol (-)-(1S,2R,5S)-1b was obtained from (-)-1a in 72% yield by a two-reaction sequence involving methylation and one-pot Mitsunobu esterification-hydrolysis.
Subject(s)
Prostanoic Acids/chemical synthesis , Esterification , Hydrolysis , Molecular Structure , Prostanoic Acids/chemistry , StereoisomerismABSTRACT
BACKGROUND: Asthma and chronic obstructive pulmonary disease are airway inflammatory diseases characterised by airflow obstruction. Currently approved bronchodilators such as long-acting ß(2) adrenoceptor agonists are the mainstay treatments but often fail to relieve symptoms of chronic obstructive pulmonary disease and severe asthma and safety concerns have been raised over long-term use. The aim of the study was to identify the receptor involved in prostaglandin E(2) (PGE(2))-induced relaxation in guinea pig, murine, monkey, rat and human airways in vitro. METHODS: Using an extensive range of pharmacological tools, the relaxant potential of PGE(2) and selective agonists for the EP(1-4) receptors in the presence and absence of selective antagonists in guinea pig, murine, monkey, rat and human isolated airways was investigated. RESULTS: In agreement with previous studies, it was found that the EP(2) receptor mediates PGE(2)-induced relaxation of guinea pig, murine and monkey trachea and that the EP(4) receptor mediates PGE(2)-induced relaxation of the rat trachea. These data have been confirmed in murine airways from EP(2) receptor-deficient mice (Ptger2). In contrast to previous publications, a role for the EP(4) receptor in relaxant responses in human airways in vitro was found. Relaxant activity of AH13205 (EP(2) agonist) was also demonstrated in guinea pig but not human airway tissue, which may explain its failure in clinical studies. CONCLUSION: Identification of the receptor mediating PGE(2)-induced relaxation represents a key step in developing a novel bronchodilator therapy. These data explain the lack of bronchodilator activity observed with selective EP(2) receptor agonists in clinical studies.
Subject(s)
Asthma/drug therapy , Bronchodilator Agents/pharmacology , Dinoprostone/pharmacology , Pulmonary Disease, Chronic Obstructive/drug therapy , Receptors, Prostaglandin E/agonists , Trachea/drug effects , Alprostadil/analogs & derivatives , Alprostadil/pharmacology , Animals , Asthma/physiopathology , Bridged Bicyclo Compounds, Heterocyclic , Dinoprostone/analogs & derivatives , Fatty Acids, Unsaturated , Guinea Pigs , Humans , Hydrazines/pharmacology , Macaca fascicularis , Methyl Ethers/pharmacology , Mice , Mice, Inbred C57BL , Naphthalenes/pharmacology , Phenylbutyrates/pharmacology , Prostanoic Acids/pharmacology , Pulmonary Disease, Chronic Obstructive/physiopathology , Rats , Rats, Sprague-Dawley , Receptors, Prostaglandin E/physiology , Regression Analysis , Species Specificity , Trachea/physiology , Xanthones/pharmacologyABSTRACT
The accumulation of unfolded or misfolded proteins in the endoplasmic reticulum (ER) is known to activate the ER, which is termed ER stress. Here, we demonstrated that amyloid precursor protein (APP) is a novel mediator of ER stress-induced apoptosis through the C/EBP homologous protein (CHOP) pathway. Expression of APP mRNA was elevated by tunicamycin- or dithiothreitol-induced ER stress. The levels of C83 and APP intracellular domain (AICD) fragments, which are cleaved from APP, were significantly increased under ER stress, although the protein level of full-length APP was decreased. Cellular viability was reduced in APP-over-expressing cells, which was attenuated by treatment with a gamma-secretase inhibitor, N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT). Cellular viability was also reduced in AICD-FLAG-over-expressing cells. The mRNA and protein levels of CHOP, an ER stress-responsive gene, were remarkably increased by APP over-expression, which was attenuated by treatment with DAPT. CHOP mRNA induction was also found in AICD-FLAG-over-expressing cells. Cell death and CHOP up-regulation by ER stress were attenuated by APP knockdown. Data obtained with a luciferase assay and chromatin immunoprecipitation assay indicated that AICD associates with the promoter region of the CHOP gene. In conclusion, ER stress-induced APP undergoes alpha- and gamma-secretase cleavage and subsequently induces CHOP-mediated cell death.
Subject(s)
Amyloid beta-Protein Precursor/metabolism , Endoplasmic Reticulum/metabolism , Signal Transduction/physiology , Stress, Physiological/drug effects , Transcription Factor CHOP/metabolism , Amyloid beta-Peptides/metabolism , Amyloid beta-Protein Precursor/genetics , Cell Death/drug effects , Cell Line/ultrastructure , Chromatin Immunoprecipitation/methods , Dipeptides/pharmacology , Dithiothreitol/pharmacology , Endoplasmic Reticulum/drug effects , Enzyme Inhibitors/pharmacology , Humans , L-Lactate Dehydrogenase/metabolism , Neuroblastoma , Prostanoic Acids/metabolism , Protein Structure, Tertiary/physiology , RNA, Messenger/metabolism , RNA, Small Interfering/pharmacology , Signal Transduction/drug effects , Time Factors , Transfection , Tunicamycin/pharmacology , Tyrosine/metabolismABSTRACT
In a previous study, we reported that Alzheimer's disease-associated presenilin-2 interacts with a LIM-domain protein, namely, DRAL/FHL2/SLIM3. In this study, we investigated whether DRAL modifies the metabolism of the amyloid precursor protein (APP). We used small interfering RNA (siRNA) to knockdown DRAL in COS7 and HEK293 cells that stably overexpress APP695. We found that the knockdown was accompanied by a decrease in the amount of secreted alpha-secretase-cleaved APP and the membrane-bound C-terminal fragment C83 and an increase in the amount of secreted beta-amyloid peptide (Abeta) from the cells. We also found that in addition to a disintegrin and metalloprotease (ADAM)-17, DRAL binds to ADAM-10. Thus, DRAL may be involved in the processing of APP through the alpha-secretase pathway.
Subject(s)
Amyloid beta-Protein Precursor/metabolism , Homeodomain Proteins/metabolism , Muscle Proteins/metabolism , Transcription Factors/metabolism , ADAM Proteins/metabolism , ADAM10 Protein , ADAM17 Protein , Amyloid Precursor Protein Secretases/metabolism , Animals , Cell Line, Transformed , Chlorocebus aethiops , Cricetinae , Humans , LIM-Homeodomain Proteins , Membrane Proteins/metabolism , Phorbol Esters/pharmacology , Prostanoic Acids/metabolism , RNA, Small Interfering/metabolism , TransfectionABSTRACT
Prostaglandin D(2) (PGD(2)) is a cyclooxygenase (COX) product of arachidonic acid that activates D prostanoid receptors to modulate vascular, platelet, and leukocyte function in vitro. However, little is known about its enzymatic origin or its formation in vivo in cardiovascular or inflammatory disease. 11,15-dioxo-9alpha-hydroxy-2,3,4,5-tetranorprostan-1,20-dioic acid (tetranor PGDM) was identified by mass spectrometry as a metabolite of infused PGD(2) that is detectable in mouse and human urine. Using liquid chromatography-tandem mass spectrometry, tetranor PGDM was much more abundant than the PGD(2) metabolites, 11beta-PGF(2alpha) and 2,3-dinor-11beta-PGF(2alpha), in human urine and was the only endogenous metabolite detectable in mouse urine. Infusion of PGD(2) dose dependently increased urinary tetranor PGDM > 2,3-dinor-11beta-PGF(2alpha) > 11beta-PGF(2alpha) in mice. Deletion of either lipocalin-type or hemopoietic PGD synthase enzymes decreased urinary tetranor PGDM. Deletion or knockdown of COX-1, but not deletion of COX-2, decreased urinary tetranor PGDM in mice. Correspondingly, both PGDM and 2,3-dinor-11beta-PGF(2alpha) were suppressed by inhibition of COX-1 and COX-2, but not by selective inhibition of COX-2 in humans. PGD(2) has been implicated in both the development and resolution of inflammation. Administration of bacterial lipopolysaccharide coordinately elevated tetranor PGDM and 2,3-dinor-11beta-PGF(2alpha) in volunteers, coincident with a pyrexial and systemic inflammatory response, but both metabolites fell during the resolution phase. Niacin increased tetranor PGDM and 2,3-dinor-11beta-PGF(2alpha) in humans coincident with facial flushing. Tetranor PGDM is an abundant metabolite in urine that reflects modulated biosynthesis of PGD(2) in humans and mice.
Subject(s)
Prostaglandin D2/analogs & derivatives , Prostaglandin D2/biosynthesis , Prostanoic Acids/urine , Animals , Chromatography, High Pressure Liquid , Cyclooxygenase Inhibitors/pharmacology , Dimerization , Humans , Intramolecular Oxidoreductases/deficiency , Intramolecular Oxidoreductases/genetics , Intramolecular Oxidoreductases/metabolism , Lactones/pharmacology , Lipocalins/genetics , Lipocalins/metabolism , Male , Mass Spectrometry , Mice , Mice, Inbred C57BL , Mice, Knockout , Prostaglandin D2/urine , Sulfones/pharmacologyABSTRACT
Cerebral amyloid angiopathy (CAA) is characterized by the degeneration of cerebral microvascular smooth muscle cells (MV-SMC) and the replacement of normal vessel wall components by beta-amyloid (Abeta) protein. Little is known regarding the mechanisms of SMC degeneration in CAA. The effects of anoxia on the metabolism of the amyloid precursor protein (APP) were studied to investigate the MV-SMC response to anoxic stress and its possible role in the pathogenesis of CAA. MV-SMC exposed to chronic anoxia (24-48 hours) showed a decrease in expression of the 2 putative alpha-secretase enzymes, mature TACE (TNFalpha-converting enzyme) and ADAM10 (a disintegrin and metalloprotease). A concomitant decrease in the alpha-secretase cleavage products sAPPalpha and C83 was observed. Investigation of mRNA expression showed an increase in TACE and a sharp decrease in ADAM10 at 24 hours. Exposing MV-SMC to hypoxia (1% O2) revealed a different pattern of expression with no significant change in TACE protein, but an increase in TACE mRNA occurring at a later time point (48 hours). There was no change in ADAM10 mRNA expression, but a reduction in mature ADAM10 with a parallel increase in immature ADAM10 protein. These results demonstrate a requirement for oxygen in the regulation of the alpha-secretase pathway during APP metabolism.
Subject(s)
Amyloid beta-Protein Precursor/metabolism , Hypoxia/metabolism , Muscle, Smooth, Vascular/cytology , Myocytes, Smooth Muscle/metabolism , ADAM Proteins/metabolism , ADAM10 Protein , ADAM17 Protein , Amyloid Precursor Protein Secretases , Blotting, Western/methods , Cells, Cultured , Cerebral Cortex/cytology , Gene Expression Regulation/physiology , Humans , Hypoxia/pathology , Immunoprecipitation , Membrane Proteins/metabolism , Prostanoic Acids/metabolism , RNA, Messenger/genetics , RNA, Messenger/metabolism , Reverse Transcriptase Polymerase Chain Reaction/methods , Time FactorsABSTRACT
A cobalt-diamine complex catalyzes the cross-coupling reactions of primary and secondary alkyl halides with aryl Grignard reagents. It is confirmed that oxidative addition of alkyl halide to cobalt proceeds via a radical process. Optically pure Ueno-Stork halo acetals undergo diastereoselective cross-coupling reactions, the products of which are transformed into optically active THF derivatives. A sequential radical cyclization/arylation reaction under cobalt catalysis provides extremely short access to a synthetic prostaglandin AH13205.
Subject(s)
Cobalt/chemistry , Hydrocarbons, Halogenated/chemistry , Magnesium/chemistry , Prostanoic Acids/chemical synthesis , Catalysis , Cyclization , Organometallic Compounds/chemistry , StereoisomerismABSTRACT
Durante el período de 1960 y los finales del siglo XX, distintos investigadores concentraron esfuerzos para comprender la regulación de la biosíntesis y el metabolismo de los Eicosanoides. Estas moléculas, de carácter autacoide, se originan de los ácidos grasos poliinsaturados de 20 átomos de C, de allí que su nombre se derive del prefijo griego EICO, veinte. Las acciones fisiológicas y en ciertas condiciones, fisiopatológicas, ejercidas por estas moléculas ocurre en un orden de concentración µmolar o menor y permanecen activas por espacios de tiempo que fluctúan entre los segundos y los minutos. En ese fructífero período del siglo XX, se logró identificar: 1- el ácido araquidónico como el principal precursor de los eicosanoides, 2- el compartimiento de los fosfolípidos de membrana como el almacén celular del sustrato precursor y 3- a las fosfolipasas, como las enzimas requeridas para liberar al ácido graso precursor, que hace posible su acceso a la maquinaria enzimática de síntesis de eicosanoides. En función de su estructura molecular surgen dos grandes grupos de eicosanoides, el que agrupa a los cíclicos o prostanoides, cuyo precursor universal es la prostaglandina H (PGH), un endoperóxido cíclico sintetizado por la enzima prostaglandina endoperóxido sintasa, mejor conocida por su acrónimo, COX, de cicloxigenasa; y el que agrupa a los lineales: leucotrienos, lipoxinas, y epóxidos entre otros, que son el producto de distintas rutas enzimáticas incluyendo a la lipoxigenas y las citocromo oxidasas. Esta revisión presenta los hallazgos más importantes en la historia de los prostanoides
Subject(s)
Autacoids , Eicosanoids , Prostanoic Acids , Biochemistry , VenezuelaABSTRACT
Prostanoids and cannabinoids have ocular hypotensive and neuroprotective properties. The effect of the prostanoid AH13205 (EP2), the thromboxane-mimetic U46619, the cannabinoid (CB) agonists WIN55212-2 and CP 55,940, endothelin-1 (ET-1) and 8-bromo-cAMP on the membrane currents of trabecular meshwork (TM) cells were measured using the patch-clamp technique and compared to their effects on TM contractility. Previous studies show relaxation of TM to AH 13205 and other substances that elevate cAMP, while U46619 and endothelin-1 contract TM. This study shows that after contraction (100%) with carbachol (10(-6)m), the CB agonist CP 55,940 dose-dependently reduced contractility to 83+/-4% (n=9) (10(-6)m) and 61+/-10%, (n=7) (10(-5)m). In the presence of both the CB1 antagonist AM251 (10(-6)m) and CP 55,940 (10(-5)m), the contractile response to carbachol reached 84+/-3% (n=6) of the original level. In patch-clamp experiments, membrane permeable 8-bromo-cAMP (10(-4)m) had no effect on currents of TM cells. In contrast, AH 13205 and two cannabinoids reversibly enhanced outward current through high-conductance Ca(2+)-activated K(+) channels (BKCa, BK, maxi-K) to the following values (in % of the initial value at 100 mV): AH 13205 (10(-5)m): 200+/-28% (n=6), CP 55,940 (10(-6)m): 196+/-33% (n=7), CP 55,940 (10(-5)m): 484+/-113% (n=7), WIN55212-2 (10(-5)m): 205+/-41% (n=10). Iberiotoxin (10(-7)m) completely blocked these responses. The current response to CP 55,940 (10(-5)m) could be partially blocked by the CB1 antagonist AM251 (10(-6)m). Conversely, the contractile agents in this study either caused a transient reduction in outward current (ET-1(5x10(-8)m)) or had no effect (U46619 (10(-6)m)). We conclude that stimulation of EP2 and CB1 receptors in TM is coupled to the activation of BKCa channels via a non-diffusible second messenger cascade. This effect may contribute to the relaxant activity of EP2 and CB1 agonists in isolated TM strips, modulating ocular outflow.
